Madrigal Pharmaceuticals’ Q2 2026 results reflect meaningful revenue growth from its FDA accelerated-approved therapy Rezdiffra, launched in the U.S. in April 2024 and in Germany in September 2025. The company continues to invest heavily in expanding its commercial infrastructure across geographies while maintaining robust R&D efforts to support indication expansion and new product development. Despite ongoing losses typical of biotech at this stage, Madrigal holds a strong liquidity position underpinned by cash of $293 million and manageable debt totaling approximately $472 million as of June 2026. The firm faces typical industry risks including regulatory uncertainties, capital intensity, and competitive pressure but has strategic licensing agreements and a growing product portfolio that could extend its market reach.